Cumberland Pharma acquires U.S. rights to Nordic’s injectable methotrexate

Cumberland Pharmaceuticals (NSDQ:CPIX) said today that it acquired exclusive U.S. rights to Nordic Group‘s injectable methotrexate product line to treat rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis.

Nordic Group has registered the product line for patient use in European countries, so Cumberland will register and commercialize the products in the U.S.

Get the full story at our sister site, Drug Delivery Business News

The post Cumberland Pharma acquires U.S. rights to Nordic’s injectable methotrexate appeared first on MassDevice.

from MassDevice http://ift.tt/2fxgizI